Development and pharmacological characterization of "caged" urotensin II analogs

Peptides

Volumn 26, Issue 8, 2005, Pages 1475-1480

  Bourgault, Steve ^a   Létourneau, Myriam ^a   Fournier, Alain ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Caged; Dimethoxynitrobenzyl; Photolabile; Urotensin II

Indexed keywords

UROTENSIN II;

ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; MALE; MASKING; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RADIATION EXPOSURE; RAT; RECEPTOR AFFINITY; ULTRAVIOLET RADIATION;

ANIMALS; AORTA, THORACIC; HUMANS; KINETICS; MALE; PEPTIDES, CYCLIC; PHOTOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; ULTRAVIOLET RAYS; UROTENSINS;

MAMMALIA;

EID: 22544469405     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.03.019     Document Type: Conference Paper

References (29)

1. S.R. Adams, and R.Y. Tsien Controlling cell chemistry with caged compounds Annu. Rev. Physiol. 55 1993 755 784
2. R.S. Ames, H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, and A.M. Romanic Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 Nature 401 1999 282 286
3. D.J. Behm, S.M. Harrison, Z. Ao, K. Maniscalco, S.J. Pickering, and E.V. Grau Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice Br. J. Pharmacol. 139 2003 464 472
4. G. Bkaily, S. Choufani, S. Sader, D. Jacques, P. d'Orleans-Juste, and M. Nader Activation of sarcolemma and nuclear membranes ET-1 receptors regulates transcellular calcium levels in heart and vascular smooth muscle cells Can. J. Physiol. Pharmacol. 81 2003 654 662
5. B. Boivin, D. Chevalier, L.R. Villeneuve, E. Rousseau, and B.G. Allen Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes J. Biol. Chem. 278 2003 29153 29163
6. E. Brailoiu, C.M. Filipeanu, A. Tica, C.P. Toma, D. de Zeeuw, and S.A. Nelemans Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta Br. J. Pharmacol. 126 1999 1133 1138
7. A. Brkovic, A. Hattenberger, E. Kostenis, T. Klabunde, S. Flohr, and M. Kurz Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay J. Pharmacol. Exp. Ther. 306 2003 1200 1209
8. Y. Coulouarn, I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint, and J.C. Beauvillain Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord Proc. Natl. Acad. Sci. U.S.A. 95 1998 15803 15808
9. S.A. Douglas Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr. Opin. Pharmacol. 3 2003 159 167
10. S.A. Douglas, D. Dhanak, and D.G. Johns From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function Trends. Pharmacol. Sci. 25 2004 76 85
11. S.A. Douglas, and E.H. Ohlstein Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease Trends. Cardiovascul. Med. 10 2000 229 237
12. K. Du, P. Nicole, A. Couvineau, and M. Laburthe Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production Biochem. Biophys. Res. Commun. 230 1997 289 292
13. P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, and M. Wenz Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure Proc. Natl. Acad. Sci. U.S.A. 84 1987 7413 7417
14. S. Flohr, M. Kurz, E. Kostenis, A. Brkovich, A. Fournier, and T. Klabunde Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II J. Med. Chem. 25 2002 1799 1805
15. P. Grieco, A. Carotenuto, P. Campiglia, E. Zampelli, R. Patacchini, and C.A. Maggi A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge J. Med. Chem. 26 2002 4391 4394
16. H. Itoh, Y. Itoh, J. Rivier, and K. Lederis Contraction of major artery segments of rat by fish neuropeptide urotensin II Am. J. Physiol. 252 1987 R361 R366
17. A. Kinney, H.R. Almond, J. Qi, C.E. Smith, R.J. Santulli, and L. de Garavilla Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model Angew. Chem. Int. Ed. Engl. 41 2002 2940 2944
18. K. Kristiansen, W.K. Kroeze, D.L. Willins, E.I. Gelber, J.E. Savage, and R.A. Glennon A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism J. Pharmacol. Exp. Ther. 293 2000 735 746
19. P. Labarrere, D. Chatenet, J. Leprince, C. Marionneau, G. Loirand, and M.C. Tonon Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction J. Enzyme Inhib. Med. Chem. 18 2003 77 88
20. M.C. Morris, J. Depollier, J. Mery, F. Heitz, and G. Divita A peptide carrier for the delivery of biologically active proteins into mammalian cells Nat. Biotechnol. 19 2001 1173 1176
21. R.B. Nehring, W. Meyerhof, and D. Richter Aspartic acid residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding DNA Cell Biol. 14 1995 939 944
22. P. Pan, and H. Bayley Caged cysteine and thiophosphoryl peptides FEBS Lett. 405 1997 81 85
23. D. Pearson, J.E. Shively, B.R. Clark, I.I. Geschwind, M. Barkley, and R.S. Nishioka Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes Proc. Natl. Acad. Sci. U.S.A. 77 1980 5021 5024
24. R.N. Re The intracrine hypothesis and intracellular peptide hormone action Bioessays 25 2003 401 409
25. Y. Shigeri, Y. Tatsu, and N. Yumoto Synthesis and application of caged peptides and proteins Pharmacol. Ther. 91 2001 85 92
26. Y. Tatsu, Y. Shigeri, A. Ishida, I. Kameshita, H. Fujisawa, and N. Yumoto Synthesis of caged peptides using caged lysine: application to the synthesis of caged AIP, a highly specific inhibitor of calmodulin-dependent protein kinase II Bioorg. Med. Chem. Lett. 19 1999 1093 1096
27. Y. Tatsu, Y. Shigeri, S. Sogabe, N. Yumoto, and S. Yoshikawa Solid-phase synthesis of caged peptides using tyrosine modified with a photocleavable protecting group: application to the synthesis of caged neuropeptide Y Biochem. Biophys. Res. Commun. 227 1996 688 693
28. J.W. Walker, S.H. Gilbert, R.M. Drummond, M. Yamada, R. Sreekumar, and R.E. Carraway Signaling pathways underlying eosinophil cell motility revealed by using caged peptides Proc. Natl. Acad. Sci. U.S.A. 95 1998 1568 1573
29. Y. Watai, I. Sase, H. Shiono, and Y. Nakano Regulation of nuclear import by light-induced activation of caged nuclear localization signal in living cells FEBS Lett. 488 2001 39 44